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Introduction
Retinopathy of Prematurity (ROP), first described in the 1940s [1], 
is a common ocular disease that occurs in premature babies and is the 
major cause of severe visual impairment or blindness in children living 
in the high- and middle-income countries [2]. The incidents of ROP not 
only affect the quality of life of these children in the rest of their lives, but 
can also cause numerous medical and economic burdens in the society. 
Effective and safe treatments are, therefore, vital. The emergence of 
stem cells provides an excellent therapeutic approach in ocular disease 
due to its potential in tissue regeneration by replacing the damaged 
cells as well as evoking paracrine signals to the neighboring cells, and 
thereby restoring vision. In this review, the potential application of stem 
cell therapy in ROP will be discussed.
Overview of Vision
The eye is a unique and well-designed organ that allows us to 
transduce light into signals and proceed to images in the brain, 
resulting in perception of “vision”. Such a process involves a precise 
coordination of various components. Firstly, light passes through the 
cornea and is gathered and focused via the lens onto the retina, which 
is highly vascular and consists of layers of various cell types. In the 
back of the retina, photoreceptors sense the light and transduce it into 
electric signals that are then transmitted through bipolar cells to the 
retinal ganglion cells (RGCs) located at the inner retina. These signals 
subsequently travel along the axons of RGCs, which is also known 
as the optic nerve, to the visual cortex of the brain where images are 
translated. Vision loss can be resulted from defects or abnormalities in 
any part of the above pathway, such as genetic defects, degeneration and 
chemical or physical trauma. 
Structure of Retina
The retina is highly vascularized and consists of various types of cells 
that are precisely organized into three layers of neural cell bodies: (1) the 
outer nuclear layer (ONL) filled with the nuclei of photoreceptors, (2) 
the inner nuclear layer (INL) housing the nuclei of bipolar, horizontal 
and most of the amacrine cells, as well as (3) ganglion cell layer (GCL) 
including the nuclei of RGCs and some displaced amacrine cells. In 
addition, axons and terminal endings of these retinal neural cells form 
two synaptic layers: the outer plexiform layer (OPL) and the inner 
plexiform layer (IPL) [3] (Figure 1). 
Dual blood supply is present in the retina to support its daily 
metabolic demand: the choroidal vessels provide oxygen and nutrients 
to the photoreceptors located at the outer most layer of the retina while 
other inner retinal cells, such as RGCs and Müller cells, are nourished 
by the intra-retinal circulation [4]. These retinal micro-vessels contain 
an inner lining of non-fenestrated endothelial cells surrounded by 
pericytes and glial processes. More importantly, all of these components 
are joined together by tight junctions in order to maintain the integrity 
of the blood retinal barrier [5].
Retinopathy of Prematurity
ROP, which is a major complication of preterm births, contributes 
to the leading cause of childhood blindness. The prevalence of ROP 
is associated with low birth weight, low gestational age, supplemental 
oxygen therapy [6], low insulin-like growth factor (IGF-1) level [7], and 
genetic mutation [8]. Due to the increased survival of extreme low birth 
weight infants (≤ 1000 g) with improved neonatal care, the risk for ROP 
has also been increased [9].
ROP is a biphasic disease with a first phase of vessel growth 
cessation and a second phase of vessel proliferation (also known as 
“neovascularization”). In human, the development of retinal vasculature 
starts from the 16th week of gestation and finishes just before term, i.e. 
the 40th week of gestation, in a central-to-peripheral manner [10]. The 
relative hyperoxia of the extra-uterine environment with or without 
supplemental oxygen during hospitalization, together with a deficiency 
of autoregulation, result in an increase of free oxygen radical and a 
decrease of vascular endothelial growth factor (VEGF) in the premature 
retina and subsequently the regression of developed retinal vessels. 
Incomplete development of the retinal vasculature therefore limits 
retinal blood circulation, leading to a peripheral avascular a vascular 
zone in the retina of preterm infants. However, as the infants grow, the 
non-vascularized retina becomes increasingly metabolically active and 
more oxygen is in turn required, resulting in tissue hypoxia which then 
stimulates vessel proliferation. In severe cases, this proliferation triggers 
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Abstract
Retinopathy of Prematurity (ROP) is a leading cause of childhood blindness that severely affecting the quality of 
life of these children. Few treatment options are available but without favorable outcomes. Stem cell therapy, through 
its proven potential in tissue regeneration, provides an attractive therapeutic approach in treating ROP and thereby 
restoring vision.
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uncontrolled pathological regrowth of the overstated, disorganized, 
fragile, and leaky vessels from the retina into the vitreous, proceeding 
to hemorrhage and cloudy vision. Fibrous scar is eventually formed and 
retraction of which can result in detachment of retina from the retina 
pigment epithelium and even blindness if remains untreated [4,6,8,11]. 
In general, the extent of human ROP is categorized into five stages 
based on the vasculature [12,13] (Figure 2 and Table 1).
In addition to the vascular abnormalities, reduced visual acuity 
[14,15] and neuronal changes [16-19] have also been reported. 
Alterations of electroretinographic (ERG) responses have been reported 
in infants and children with a history of ROP. Lower saturated amplitude, 
decreased sensitivity and prolonged deactivation of rod photoreceptors 
were observed [16-20] and these deficits appeared to persist long after 
ROP has been resolved [17,19]. In addition, attenuated post-receptor 
responses were also present. Although these deficits could be improved 
in children with a history of mild ROP, they remained in the severe 
cases [16,19,21].
Current Treatments
Current treatments of ROP aim to target the pathological 
neovascularization and include retinal cryotherapy, laser 
photocoagulation and anti-VEGF therapy [6,11,12]. Retinal 
cryotherapy and laser photocoagulation have been proven to be 
effective in ablation of the avascular immature retina in infants with 
active ROP [12]. A 15-year follow-up study of cryotherapy has shown a 
>40% decreased unfavorable structural outcomes and a 30% decreased 
unfavorable visual outcomes [13]. However, side effects such as lid 
edema, laceration, hemorrhage of conjunctiva as well as preretinal 
and vitreous hemorrhage have been observed in this treatment [22]. 
Later, a shift from cryotherapy to laser photocoagulation was adopted 
due to better structural and functional outcomes [22]. Laser therapy is 
more convenient and technically easier, with less ocular and systemic 
adverse effects as well as reduced lesions to the external eye surface and 
sclera, and therefore used as a mainstay therapy. However, considerable 
complications of cornea, iris and lens burns, corneal edema, cataract 
formation, intraocular hemorrhage, and choroidal rupture have been 
reported due to laser treatment [8,22]. 
Over the last two decades, extensive research has focused on the 
development of ROP. It is found that neovascularization is partly 
resulted from an up-regulation of VEGF; therefore, intravitreal injection 
of specific anti-VEGF antibody can potentially neutralize the excessive 
amount of VEGF and may ameliorate the pathological vessel sprouting. 
The off-label use of the VEGF antibody, e.g. bevacizumab, is currently 
tested in clinical trials in neovascular retinopathy such as age-related 
macular degeneration, diabetic retinopathy and retinal vein occlusion 
[8,23]. Small-sized clinical trials of bevacizumab in ROP have also 
Figure 1: Layers of the human retina.  The retina mainly contains three layers of neural cell bodies (from basal to vitreal): ONL with nuclei of photoreceptors; INL with 
nuclei of horizontal cells, bipolar cells and most amacrine cells; GCL with nuclei of RGCs and some displaced amacrine cells.  In addition, the axons and terminals of 
the retinal neurons form two synaptic layers: OPL and IPL  [3].
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been conducted. Decreased pupillary rigidity and complete regression 
of retinal neovascularization were observed after intravitreal injection 
of bevacizumab while the side effects of laser therapy such as retinal 
scarring were avoided [23]. However, another clinical trial reported 
leakage of intravitreal bevacizumab into the general circulation, which 
significantly decreased plasma VEGF even after seven weeks [24]. 
The use of anti-VEGF therapy in ROP is still uncertain owing to the 
controversial results in the above studies and missing long-term clinical 
data [25].
In severe cases of ROP involving retinal detachment, scleral 
buckling procedure with or without vitrectomy is applied, although the 
resulting visual outcome is usually poor [12].
Animal Model of ROP: Oxygen-Induced Retinopathy
In order to investigate the pathogenesis of ROP, various animal 
models of oxygen-induced retinopathy (OIR) have been applied in 
several species including mice, rats, dogs, cats and pigs [26]. In brief, 
newborn animals are exposed to hyperoxia and returned to room air, 
resulting in relative hypoxia and neovascularization that mimic the two 
phases of human ROP. Both mouse and rat models of OIR are commonly 
used for investigating vascular and neuronal changes after hyperoxic 
exposure. In the mouse model, postnatal day 7 (P7) neonatal mice with 
their nursing dams are put into a 75% oxygen chamber for five days 
(P12) and then returned to room air [27]. In the rat model, new-born 
pups (P0) with their mother are placed into an incubator where oxygen 
is cycled between 50% and 10% every 24 hours for fourteen days [28]. 
In the mouse model of OIR, vessel loss in the central area of 
retina is observed immediately after five days of hyperoxic exposure 
(P12). Neovascularization extending from the inner retina into the 
vitreous begins at two days after the return to room air (P14), peaks 
on P17 and is gradually regressed and spontaneously resolved by P25 
[27,29] (Figure 3). In the rat model of OIR, blood vessel regression is 
observed in the peripheral area of the retina on P14 and strong pre-
retinal neovascularization is observed on P18 [28]. Besides the vascular 
changes, neuronal changes are also observed in these OIR models. In 
addition to the altered ERG responses in human as described earlier, 
Progression 
of ROP Characteristics
Stage 1 A thin, tortuous, grey-white demarcation line is formed between 
the vascular and avascular retina
Stage 2 A white or grey ridge is developed from demarcation line and small 
isolated neovascular tufts are observed posterior to it
Stage 3 Neovascular vessels extend from the retina into the vitreous due 
to extraretinal fibrovascular proliferation; hemorrhage of blood 
vessels is observed in both of the retina and vitreous
Stage 4 Partial retinal detachment from the extreme periphery into the 
central retina
Stage 5 Total retinal detachment
Table 1: Disease progression of different stages of human ROP.
Figure 2: Progression of retinopathy of prematurity.  (a) A thin, tortuous, grey-white line is formed and separates the avascular immature peripheral retina from the 
vascularized posterior retina.  (b) As ROP progresses, the demarcation line develops into a ridge of tissue.  Blood vessels enter the ridge and small isolated neovascular 
tufts may be seen.  (c) Neovascular vessels extend from the retina into the vitreous due to the fibrovascular proliferation.  (d) The progression of fibrovascular 
proliferation leads to retinal detachment  [12].
Citation: Lai AKW, Fu ZJ, Lo AC (2013) Stem Cell Therapy for Retinopathy of Prematurity. Anat Physiol 3: 126. doi:10.4172/2161-0940.1000126
Page 4 of 7
Volume 3 • Issue 2 • 1000126Anat PhysiolISSN:2161-0940 Physiol, an open access journal 
neuronal dysfunction of rods and inter-retinal neurons has also been 
shown in rat models of OIR. Deficits in rods and post-receptors ERG 
responses were observed [15,30-32]. Consistent with the pathology in 
human ROP, the sensitivity of post-receptors can be recovered but not 
for rod photoreceptors [31]. In addition, morphological studies showed 
disrupted rod outer segment and neurochemical changes in bipolar 
and amacrine cells [15,30]. Moreover, a small loss of rod photoreceptor 
ERG amplitude and a significant loss of post-receptor ERG amplitude 
together with significantly reduced INL and IPL thickness have been 
observed in a mouse model of OIR [33]. 
Although the rat OIR model mimics human ROP with a peripheral 
avascular zone, the mouse model of OIR is sometimes more preferred 
due to easier genetic manipulation, which provides a powerful tool for 
pathogenetic investigations [34]. In addition, the retinal vasculature 
developmental stages from the superficial layer to the deep layer in 
mouse are well described. Most importantly, the stages that occur within 
the two weeks after birth in mouse approximate to those in premature 
infants at 16th to 20th weeks of gestation [27]. These characteristics 
facilitate the mouse OIR model as a convenient and most widely 
used animal model to study ROP as well as other ischemia-associated 
retinopathy, such as diabetic retinopathy and retinal vein occlusion 
[35].
Ocular Stem Cells
A variety of region-specific ocular stem cells were being identified 
since the 1970s. Several subtypes of stem cells were discovered in the 
limbus (also called corneal endothelium) [36-38], conjunctiva and 
trabecular meshwork [39,40] in the anterior segment. Long term 
clinical studies showed that transplantation of autologous limbal stem 
cells obtained from the healthy eye could heal the damaged cornea with 
limbal stem cell deficiency resulting from severe ocular surface burns, 
microbial infection, chemotherapy and inflammatory diseases [41,42].
In the posterior segment, retinal progenitor cells were also identified 
in the pigmented ciliary margin of adult mouse retina [43] and in 
human fetal retina at the 13th week of gestation [44]. A sub-population of 
Müller stem cells was also identified in the human retina. Spontaneous 
immortalization was observed in these cells under optimal condition 
in vitro, generating the Moorfields/Institute of Ophthalmology (MIO) 
cell lines [45-47]. It was shown that these MIO cells could migrate into 
the ONL and express rhodopsin (a marker of photoreceptor cells), 
into the INL and expressed HuD (a marker of ganglion cells), as well 
as into the GCL and express calretinin (a marker of ganglion cells 
and amacrine cells) at 14 days after sub-retinal injection in normal 
neonatal Lister hooded rats [46] (Table 2). Moreover, a population 
of very small embryonic/epiblast-like stems cells (Sca-1+Lin-CD45-), 
which amounted to 1.5% of neonatal mouse retina, was identified [48]. 
These cells not only had the ability to differentiate into the eye lineages 
but also could differentiate into cells expressing markers of the three 
embryonic layers in vitro.
Stem Cells in ROP Patients
A clinical study evaluated the circulating stem cell populations 
in preterm infants with and without ROP at 10 weeks after delivery 
[49]. Two populations, namely very small embryonic-like stem cells 
(VSEL-SCs, Lin-CXCR4+CD45-) and endothelial progenitor cells 
(EPCs, CD34+CD133+CD144+) were found to be increased in the 
peripheral blood collected from the preterm patients. In patients 
with ROP, the amount of these EPCs was significantly higher when 
compared with those without ROP. Yet, no difference was observed in 
the population of circulating cells enriched in hematopoietic stem cells 
(Lin-CXCR4+CD45+) amongst the preterm infants with or without ROP 
and the full-term controls. The authors suggested that the elevation 
of circulating VSEL-SCs in the preterm infants could be the result in 
response to hypoxia in ROP, although they did not rule out the possibility 
that such increase could be associated with the physiological conditions 
in immature infants. They also hypothesized that the systemic EPC 
mobilization was also involved during neovascularization in the 
proliferative phase of ROP and normal vascularization of the retina of 
individual without ROP; however, whether such increment of EPC was 
the cause or consequence of ROP development was still unknown.
It has been reported that VSEL-SCs are small primitive cells with a 
cell size of 3-5 µm in human cord blood-derived cells and of 2-4 µm in 
mouse bone marrow cells. These cells have a high nucleus-to-cytoplasm 
ratio, with euchromatin and diploid number of chromosomes in the 
nucleus surrounded by a tiny rim of cytoplasm [50]. VSEL-SCs are 
present in umbilical cord blood [51], bone marrow, brain and other 
organs [52,53]. They express early embryonic transcription factors, such 
as octamer-4 (Oct-4), NANOG, REX, and stage-specific embryonic 
antigen (SSEA-1) [50,52], suggesting that they are deposited during 
embryogenesis and therefore, can be used as a source of pluripotent 
stem cells in adult tissue [54]. Clinical studies showed that VSEL-SCs, 
which represent a pool of mobile stem cells, could be mobilized in the 
peripheral blood upon hypoxia-associated injuries, such as stroke [55] 
and acute myocardial infarction [56]. The role of VSEL-SCs will need to 
be further investigated. 
Stem Cell Therapy in OIR
Using animal models of ROP, a number of groups revealed that 
different populations of stem cells could promote vascular repair [57-
63]. By intravitreal injection of adult mouse bone marrow-derived 
lineage negative (Lin-) or CD44 (hyaluronic acid receptor)-rich myeloid 
progenitor cells in the mouse OIR model, Ritter et al. [57] found that 
these not only were able to migrate to the avascular regions of the 
neonatal retina, but also had the ability to differentiate into microglia. 
Normalization of vasculature was further confirmed by a significant 
reduction of the obliterated and neovascular areas in the retina of 
the transplanted animals. In order to examine the potential long-
term side effects of the transplantation, morphological and functional 
studies were carried out. No teratoma, tumor, or abnormality in the 
different retinal layers was observed in the transplanted retina. In 
addition, no difference in the light-adapted cone or dark-adapted rod 
Figure 3: Schematic diagram of the mouse OIR model.  Neonatal mice and 
their nursing dam are placed into a 75% oxygen chamber from postnatal day 7 
(P7) for five days.  During this period, the growth of retinal vessels is inhibited, 
resulting in significant vessel loss in the central area of the retina.  The animals 
are then returned to room air on P12.  Hypoxia-associated pathological 
neovascularization begins at two days after the return to room air (P14) and 
reached its maximum on P17.  Neovascularization is gradually regressed and 
spontaneously resolved by P25 [29].
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ERG responses was observed in the transplanted eye when compared 
with the OIR controls 6 months after transplantation. However, when 
bone marrow-derived CD44+ cells with targeted deletion of hypoxia-
inducible factor-1α (HIF-1α) in the myeloid lineage were applied in 
the OIR model, the rescue effects were abolished. This suggested that 
the expression of myeloid-specific HIF-1α was required to promote the 
vascular repair. Moreover, injection of Lin-myeloid progenitor cells to 
P2 neonatal mice showed that these cells homed to astrocytes in the 
early stage (P6) and incorporated into the retinal vasculature during the 
later stage (P9- P16) of retinal development [58]. Upon retinal injuries 
by photocoagulation or needle tip in adult mice, these injected cells 
selectively migrated to the injured site and targeted the activated glial 
cells. When Lin- myeloid progenitor cells were injected to transgenic 
rd/rd neonatal mice, the spontaneous degeneration of vasculature was 
ceased while preserving the normal vasculature [58]. 
The incorporation ability of another sub-group of myeloid 
progenitor cells (Lin-Sca-1+, also called bone marrow-derived EPCs) 
in mouse OIR model was also reported by Nakagawa et al. [59]. In 
this study, the cells were injected into the irradiated neonatal mice via 
temporal facial vein. The transplanted cells, which were co-stained with 
CD11b (a leukocyte/monocyte marker) and with arborescent shape, 
were detectable outside the retinal vessels. Although the number of 
incorporated cells was attenuated in the intact vascular network of 
the OIR mice on P12 when compared with the controls, it reached 
the same level on P17. Interestingly, almost an equivalent amount of 
cells was also found to incorporate into vascular tufts in the OIR mice, 
suggesting that they may play a role in conversion of the pathologic 
microvasculature to intact vascular network.
Another candidate in cell-based therapy for ROP is EPCs derived 
from myeloid stem cells [60]. Due to the nature of heterogeneity 
of these cells, Medina et al. [61] isolated two sub-groups of EPCs, 
outgrowth endothelial cells (OECs) and early EPCs (eEPCs), from 
human peripheral blood and studied their therapeutic potential in 
ischemic retinopathy using the mouse OIR model. Both OECs and 
eEPCs expressed CD31 endothelial marker. Hematopoietic markers, 
such as CD45 and CD14, were absent in OECs but were abundant in 
eEPCs whereas the expression of stem cell-associated surface markers, 
CD34, CD133 and CD117, are higher in the OECs when compared 
with those in eEPCs [61,62]. At 3 days after intravitreal injection of 
OECs, significant incorporation of OECs was observed in the resident 
retinal vasculature together with tube formation, which assisted in 
retinal vascular remodeling, in the ischemic region. The reduction 
of pathologic neovascularization in the OECs-treated retina further 
demonstrated the vascular repair ability of OECs in OIR. On the 
contrary, eEPCs only had minimal proliferative capacity and lacked 
tube-forming capacity in this study [61].
Moreover, Yoon et al. [63] showed that transplantation of the mixed 
populations of EPCs, OECs and eEPCs, synergistically promoted vessel 
formation in a mouse hind limb ischemic model. Both sub-groups of 
EPCs expressed VEGF receptors. IL-8 and matrix metalloproteinases 
(MMP)-9 were found to be secreted by eEPCs while MMP-2 was mainly 
secreted by OECs. The authors proposed that the OECs might act as a 
building block while the eEPCs contribute to the neovascularization. 
In fact, cross-talk by the secreted cytokines or other factors may exist 
between the two types of EPCs.
In summary, the therapeutic potential of stem cells in ROP 
was evident in the above animal studies, in which the pathologic 
vasculature observed in mouse OIR model was normalized after stem 
cell treatment. A summary of the potential use of various types of stem 
cells is provided in Table 2.
Future Prospective
Owing to the promising experimental results obtained in the animal 
OIR models, stem cell therapy could represent an alternative treatment 
for ROP in preterm infants. Transplantation of autologous bone 
marrow-derived stem/progenitor cells from the newborns, however, 
is traumatic and unfeasible due to the health status of the preterm 
infants and the invasive procedures in harvesting the bone marrow. 
Type of stem cell Origin of stem cells Experimental outcomes in animal models or clinical studies Potential therapeutic use
Animal models
Lin- or CD44-rich myeloid 
progenitor cells [57] Mouse bone marrow
Transplanted cells migrated to the avascular regions of the retina and 
differentiated into microglia in a mouse OIR model
Reduced the obliterated and neovascular areas in a mouse OIR model
ROP
OECs (CD31+CD34+ CD146+CD14-
CD45-) [61] Human peripheral blood
Transplanted cells incorporated into the resident retinal vasculature 
and assisted in retinal vascular remodeling with formation of tubes in a 
mouse OIR model
Reduced the avascular and neovascular areas in a mouse OIR model
ROP
eEPCs (CD14+CD31+CD45+CD34-
CD117-CD133-CD146-) [61] Human peripheral blood
Minimal proliferative capacity in a mouse OIR model
Lack of tube-formation capacity in a mouse OIR model ROP
EPCs (Lin-Sca-1+) [59] Mouse bone marrow Transplanted cells incorporated in vascular tufts in addition to the intact region in a mouse OIR model ROP
Lin- myeloid progenitor cells [58] Mouse bone marrow
Transplanted cells selectively migrated to the injured site and targeted 
the activated glial cells upon laser or mechanical injury
Transplantation of cells ceased the spontaneous degeneration of 
vasculature in transgenic rd/rd neonatal mice
Retinal degeneration
Mixed OECs and eEPCs [63] Human peripheral blood Synergistically promoted vessel formation in a mouse hind limb ischemic model
Revascularization in ischemic 
tissue
MIO cells [46] Human retina Transplanted cells migrated into the ONL, INL and GCL in normal neonatal Lister hooded rats Retinal degeneration
Very small embryonic/epiblast-like 
stem cells (Sca-1+Lin-CD45-) [48] Neonatal mouse retina
Differentiated into cells expressing markers of the three embryonic 
layers in vitro
Cell type identified but potential 
use currently unknown 
Clinical studies
EPCs (CD34+CD133+CD144+) [49] Human  peripheral blood Increase in preterm patientsHigher in patients with ROP than those without
Cell type identified but  potential 
use currently unknown
VSEL-SCs (Lin-CXCR4+CD45-) 
[49,55,56] Human peripheral blood
Increase in preterm patients
Found in peripheral blood upon hypoxia-associated injuries
Cell type identified but
potential use currently unknown
Limbal stem cells [41,42] Human limbus Permanent restoration of transparent corneal epithelium (10 year follow-up studies) Limbal stem cell deficiency
Table 2:  A summary of the experimental outcomes as well as the potential therapeutic use of various types of stem cells in animal models and clinical studies.
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Although the use of allogenic bone marrow with matched human 
leukocyte antigens (HLA) can overcome this problem, the potential of 
graft rejection cannot be excluded. On the other hand, autologous EPCs 
can be isolated from peripheral blood and expanded in vitro, thereby 
allowing subsequent transplantation. Another potential source of stem 
cells comes from umbilical cord blood (UCB), which contains a reservoir 
of a variety of stem cells, including VSEL-SCs [51], mesenchymal stem 
cell, hematopoietic stem cells and cord blood-derived embryonic-like 
stem cells [64]. Based on the phenotypic specificities of the stem cell 
sub-populations in the animal studies, they can be used as a reference 
for identification and isolation from the UCB. UCB is abundant, easily 
to harvest without harming the donors and ethical to use [65]. Further 
in vivo studies using these selected cells allow us to have a better insight 
of UCB as the alternative source of stem cells in ROP.
Conclusion
The incidence of preterm birth and its associated retinal 
prematurity are unavoidable. The emergence of stem cells therapy 
provides a potential alternative treatment for ROP. A number of studies 
showed that stem cells have regenerative ability, not only by direct 
differentiation and incorporation into the vasculature but also via a 
paracrine manner on the residential cells, thereby promoting normal 
vascularization in animal OIR models. Stem cell therapy as a medical 
treatment has ushered in a new era.
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